Teikoku Pharma USA Inc. and Teikoku Seiyaku Co. Ltd. settled Federal Trade Commission charges that they entered a pay-for-delay deal with Endo Pharmaceuticals Inc. and Watson Laboratories Inc. to increase prices on Lidoderm (FTC v. Endo Pharmaceuticals Inc., E.D. Pa., 16-cv-01440, 4/7/16).
The FTC’s consent agreement with Teikoku gets the FTC into the business of reviewing patent settlement agreements by barring Teikoku from entering “reverse payment” agreements unless it gets prior approval from the commission63 PTD, 4/1/16, 14 PLIR 469, 4/1/16, 63 HCDR, 4/1/16, 91 PTCJ 1639, 4/8/16, See previous story, 04/01/16, 63 Antitrust & Trade Regulation Daily, 4/1/16, 25 HLR 472, 4/7/16, 110 ATRR 383, 4/1/16.
The FTC’s complaint, one of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.